Tucatinib 50 mg | 99.96%
TargetMol
Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).
More Information Supplier PageTucatinib
Search Results
Tucatinib 10 mg | 99.96%
TargetMol
Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).
More Information Supplier PageTucatinib
STF-31 2 mg | 99.92%
TargetMol
STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.
More Information Supplier PageSTF-31
STF-31 10 mg | 99.92%
TargetMol
STF-31 is an inhibitor of glucose transporter 1 (GLUT1) with IC50 of 1 μM.
More Information Supplier PageSTF-31
Tipiracil hydrochloride 200 mg | 99.45%
TargetMol
Tipiralacil is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials.
More Information Supplier PageTipiracil hydrochloride
Tipiracil hydrochloride 50 mg | 99.45%
TargetMol
Tipiralacil is a thymidine phosphorylase inhibitor (TPI). Tipiracil is one of the active components in TAS-102, which is an anticancer drug candidate currently in clinical trials.
More Information Supplier PageTipiracil hydrochloride
Cevimeline hydrochloride hemihydrate 5 mg | 100.00%
TargetMol
Cevimeline hydrochloride hemihydrate is a novel muscarinic receptor agonist, used as a candidate therapeutic drug for xerostomia in Sjogren’s syndrome.
More Information Supplier PageCevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hemihydrate 50 mg | 100.00%
TargetMol
Cevimeline hydrochloride hemihydrate is a novel muscarinic receptor agonist, used as a candidate therapeutic drug for xerostomia in Sjogren’s syndrome.
More Information Supplier PageCevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hemihydrate 10 mg | 100.00%
TargetMol
Cevimeline hydrochloride hemihydrate is a novel muscarinic receptor agonist, used as a candidate therapeutic drug for xerostomia in Sjogren’s syndrome.
More Information Supplier PageCevimeline hydrochloride hemihydrate
Ipragliflozin 50 mg | 99.97%
TargetMol
Ipragliflozin is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.
More Information Supplier PageIpragliflozin
